Evidence map›Paper›PMID 37221655›Full record

ArticleObesity (Silver Spring, Md.)2023

Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin-resistant canine model.

Morvarid Kabir, Richard N Bergman, Jay Porter, Darko Stefanovski, Rebecca L Paszkiewicz, Francesca Piccinini, Orison O Woolcott, HsiuChiung Yang, V Sashi Gopaul, Linsey Stiles and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity (Silver Spring, Md.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Morvarid KabirDiabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0003-0880-3767
Richard N BergmanDiabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0003-1539-4471
Jay PorterDiabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0003-3179-6737
Darko StefanovskiUniversity of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.
Rebecca L PaszkiewiczDiabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Francesca PiccininiDiabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Orison O WoolcottDiabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
HsiuChiung YangResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
V Sashi GopaulResearch and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Linsey StilesDepartment of Endocrinology, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
Cathryn M KolkaDiabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Cedars-Sinai Medical Center · USAstraZeneca (Finland) · FIUniversity of California, Los Angeles · USUniversity of Pennsylvania · US

Funding

QUANTITATION OF FACTORS REGULATING GLUCOSE TOLERANCER01DK029867 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MARILYN ADER · 1986 to 2026
$11.0M
QUANTITATIVE STUDIES OF METABOLIC ORGAN DYNAMICSR01DK027619 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERGMAN, RICHARD NATHAN · 1986 to 2022
$6.2M
Quantitative Studies of Metabolic Organ DynamicsR37DK027619 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERGMAN, RICHARD NATHAN · 2007 to 2016
$6.2M
NIDDK NIH HHS R01 DK027619NIDDK NIH HHS R01 DK029867NIDDK NIH HHS R37 DK027619
6 · The paper itself

Abstract

objectiveSodium-glucose cotransporter 2 inhibitors (SGLT2i) promote urinary glucose excretion, induce weight loss, and reduce fat accumulation. The effects of the SGLT2i dapagliflozin (DAPA) on subcutaneous (SC) and visceral (VIS) adipose tissue function remain unclear. The objective of this study is to evaluate SC and VIS adipose tissue function in an insulin-resistant canine model.

methodsA total of 12 dogs were fed a high-fat diet (HFD) for 6 weeks and then were given a single low dose of streptozotocin (18.5 mg/kg) to induce insulin resistance. Animals were then randomized and exposed to DAPA (n = 6, 1.25 mg/kg) or placebo (n = 6) once per day for 6 weeks while remaining on the HFD.

resultsDAPA prevented further weight gain induced by the HFD and normalized fat mass. DAPA reduced fasting glucose and increased free fatty acids, adiponectin, and β-hydroxybutyrate. DAPA reduced adipocyte diameter and cell distribution. Furthermore, DAPA increased genes associated with beiging, lipolysis, and adiponectin secretion and the expression of the adiponectin receptor ADR2, in SC and VIS adipose tissue. DAPA increased AMP-activated protein kinase activity and maximal mitochondrial respiratory function, especially in the SC depot. Furthermore, DAPA reduced cytokines and ceramide synthesis enzymes in SC and VIS depots.

conclusionsFor the first time, to our knowledge, we identify mechanisms by which DAPA enhances adipose tissue function in regulating energy homeostasis in an insulin-resistant canine model.

Indexed as

InsulinInsulin ResistanceAdiponectinAdipose TissueAnimalsBenzhydryl CompoundsDogsGlucoseGlucosidesSubcutaneous FatAdiponectinBenzhydryl CompoundsdapagliflozinGlucoseGlucosidesInsulin

Identifiers

PMID37221655
PMCPMC10981466
OpenAlexW4377940560

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.